基于网络药理学和分子对接探究三棱-莪术抗乳腺癌的作用机制

doi:10.3976/j.issn.1002-4026.2022.05.004

Abstract

Abstract:

To explore the active ingredients and mechanisms of Sparganii Rhizoma-Curcumae Rhizoma herbal pair in breast cancer using network pharmacology and molecular docking. The effective active ingredients and corresponding targets of Sparganii Rhizoma and Curcumae Rhizoma were searched and screened using the traditional Chinese medicine systems pharmacology database and analysis platform,and the disease targets of breast cancer were searched using the OMIM and GeneCards databases. Cytoscape 3.7.2 software was used to construct a visual network diagram of drug-ingredient-disease-targets. A protein-protein interaction network (PPI) was constructed using STRING database platform, and the MCODE plug-in in Cytoscape was used for analysis to screen the top 10 core targets. Gene ontology and Kyoto encyclopedia of genes and genomes(KEGG) enrichment pathway analyses of the targets of action were performed using DAVID database, and the network diagram of ingredient-target-pathway was plotted. Finally, molecular docking was performed using autodock Vina and other software to verify the interaction between the core ingredients and the core targets. Seven active components and 73 action targets were obtained through screening. There were 43 common targets of Sparganii Rhizoma and Curcumae Rhizoma and breast cancer. The active components were hederagenin, beta-sitosterol, formononetin, stigmasterol, and trans-gondoic acid. The PPI network showed that the key targets were JUN, CASP3, PTGS2, ESR1, MPK14, PPARG, SIRT1, NOS3, TGFB1 and NOS2. The KEGG pathway enrichment analysis revealed 72 items. According to the P values, the first 20 items related to breast cancer were eliminated via screened, including the PI3K-Akt signaling pathway, VEGF signaling pathway, p53 signaling pathway, and MAPK signaling pathway. The molecular docking results showed that the active ingredients had strong binding ability in docking with the core targets. Therefore, our results suggest that Sparganii Rhizoma-Curcumae Rhizoma herbal pair has characteristics of a multi-ingredient, multi-target, and multi-pathway on breast cancer, which provides a theoretical basis for its clinical application in the future.

Key words: network pharmacology, molecular docking, Sparganii Rhizoma-Curcumae Rhizoma, breast cancer, mechanism

CLC Number:

R285

LIU Xue-ting, SUN Xiao-hui, ZHU Jian-min, LI Lin, LI Wen-yue. Mechanism of the anti-breast cancer effect of Sparganii Rhizoma-Curcumae Rhizoma herbal pair based on network pharmacology and molecular docking[J].Shandong Science, 2022, 35(5): 26-36.

Figures/Tables 10

Fig.1

Fig.2

Fig.3

Fig.4

Table 1

Table 2

Table 3

Fig.5

Table 4

Fig.6

References 30

[1]	SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA: A Cancer Journal for Clinicians, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660. doi: 10.3322/caac.21660 pmid: 33538338
[2]	TRAN S, HICKEY M, SAUNDERS C, et al. Nonpharmacological therapies for the management of menopausal vasomotor symptoms in breast cancer survivors[J]. Supportive Care in Cancer, 2021, 29(3): 1183-1193. DOI: 10.1007/s00520-020-05754-w. doi: 10.1007/s00520-020-05754-w
[3]	卢泰成, 许博文, 李杰. 王清任活血化瘀法在肿瘤治疗中的应用[J]. 世界中医药, 2021, 16(10): 1616-1619. DOI: 10.3969/j.issn.1673-7202.2021.10.023. doi: 10.3969/j.issn.1673-7202.2021.10.023
[4]	陈桂芬. 血瘀证乳腺癌与分子分型及预后关系的相关性研究[J]. 中国现代医药杂志, 2019, 21(7): 5-8. DOI: 10.3969/j.issn.1672-9463.2019.07.002. doi: 10.3969/j.issn.1672-9463.2019.07.002
[5]	寇露露, 刘海霞, 邵妤, 等. 三棱、莪术抗肿瘤生物活性研究[J]. 吉林中医药, 2017, 37(7): 722-724. DOI: 10.13463/j.cnki.jlzyy.2017.07.021. doi: 10.13463/j.cnki.jlzyy.2017.07.021
[6]	陈晓军, 韦洁, 苏华, 等. 莪术药理作用的研究新进展[J]. 药学研究, 2018, 37(11): 664-668. DOI: 10.13506/j.cnki.jpr.2018.11.011. doi: 10.13506/j.cnki.jpr.2018.11.011
[7]	李林, 陆兔林, 卞慧敏, 等. 莪术活血化瘀有效物质研究[J]. 上海中医药大学学报, 2004, 18(3): 40-42. DOI: 10.16306/j.1008-861x.2004.03.014. doi: 10.16306/j.1008-861x.2004.03.014
[8]	尹定聪, 杨华升. 莪术油抗肿瘤作用的研究进展[J]. 中医药导报, 2018, 24(3): 62-63. DOI: 10.13862/j.cnki.cn43-1446/r.2018.03.020. doi: 10.13862/j.cnki.cn43-1446/r.2018.03.020
[9]	袁甜, 崔琳琳, 王莹, 等. 中药网络药理学最新进展[J]. 中医药学报, 2021, 49(1): 101-106. DOI: 10.19664/j.cnki.1002-2392.210023. doi: 10.19664/j.cnki.1002-2392.210023
[10]	HSIN K Y, GHOSH S, KITANO H. Combining machine learning systems and multiple docking simulation packages to improve docking prediction reliability for network pharmacology[J]. PLoS One, 2013, 8(12): e83922. DOI: 10.1371/journal.pone.0083922. doi: 10.1371/journal.pone.0083922
[11]	CHENG L, SHI L, WU J, et al. A hederagenin saponin isolated from Clematis ganpiniana induces apoptosis in breast cancer cells via the mitochondrial pathway[J]. Oncology Letters, 2018, 15(2):1797-1743. DOI: 10.3892/ol.2017.7494. doi: 10.3892/ol.2017.7494
[12]	RAMALINGAM S, PACKIRISAMY M, KARUPPIAH M, et al. Effect of β-sitosterol on glucose homeostasis by sensitization of insulin resistance via enhanced protein expression of PPRγ and glucose transporter 4 in high fat diet and streptozotocin-induced diabetic rats[J]. Cytotechnology, 2020, 72(3): 357-366. DOI: 10.1007/s10616-020-00382-y. doi: 10.1007/s10616-020-00382-y pmid: 32124158
[13]	GAUTAM M, THAPA R K, GUPTA B, et al. Phytosterol-loaded CD44 receptor-targeted PEGylated nano-hybridPhyto-liposomes for synergistic chemotherapy[J]. Expert Opinion on Drug Delivery, 2020, 17(3): 423-434. DOI: 10.1080/17425247.2020.1727442. doi: 10.1080/17425247.2020.1727442
[14]	WU X Y, XU H, WU Z F, et al. Formononetin, a novel FGFR2 inhibitor, potently inhibits angiogenesis and tumor growth in preclinical models[J]. Oncotarget, 2015, 6(42): 44563-44578. DOI: 10.18632/oncotarget.6310. doi: 10.18632/oncotarget.6310 pmid: 26575424
[15]	贾绍华, 刘丽娜, 颜廷华. 芒柄花素诱导人乳腺癌MCF-7细胞凋亡及其氧化应激的机制[J]. 华西药学杂志, 2020, 35(4): 385-391. DOI: 10.13375/j.cnki.wcjps.2020.04.009. doi: 10.13375/j.cnki.wcjps.2020.04.009
[16]	WU Q H, WU W D, FU B S, et al. JNK signaling in cancer cell survival[J]. Medicinal Research Reviews, 2019, 39(6): 2082-2104. DOI: 10.1002/med.21574. doi: 10.1002/med.21574 pmid: 30912203
[17]	YADAV P, YADAV R, JAIN S, et al. Caspase-3: A primary target for natural and synthetic compounds for cancer therapy[J]. Chemical Biology & Drug Design, 2021, 98(1): 144-165. DOI: 10.1111/cbdd.13860. doi: 10.1111/cbdd.13860
[18]	PENG Y L, WANG Y, TANG N, et al. Andrographolide inhibits breast cancer through suppressing COX-2 expression and angiogenesis via inactivation of p300 signaling and VEGF pathway[J]. Journal of Experimental & Clinical Cancer Research, 2018, 37(1): 1-14. DOI: 10.1186/s13046-018-0926-9. doi: 10.1186/s13046-018-0926-9
[19]	YANG W, HE X, HE C J, et al. Impact of ESR1 polymorphisms on risk of breast cancer in the Chinese Han population[J]. Clinical Breast Cancer, 2021, 21(3): e235-e242. DOI: 10.1016/j.clbc.2020.10.003. doi: 10.1016/j.clbc.2020.10.003 pmid: 33281037
[20]	GAO S, DING B S, LOU W Y. microRNA-dependent modulation of genes contributes to ESR1's effect on ERα positive breast cancer[J]. Frontiers in Oncology, 2020, 10: 753. DOI: 10.3389/fonc.2020.00753. doi: 10.3389/fonc.2020.00753 pmid: 32500028
[21]	GU G W, TIAN L, HERZOG S K, et al. Hormonal modulationof ESR1 mutant metastasis[J]. Oncogene, 2021, 40(5): 997-1011. DOI: 10.1038/s41388-020-01563-x. doi: 10.1038/s41388-020-01563-x
[22]	DASHTI S, TAHERIAN-ESFAHANI Z, KHOLGHI-OSKOOEI V, et al. In silico identification of MAPK14-related lncRNAs and assessment of their expression in breast cancer samples[J]. Scientific Reports, 2020, 10(1): 1-12. DOI: 10.1038/s41598-020-65421-2. doi: 10.1038/s41598-020-65421-2
[23]	WANG L P, SHI H M, LIU Y, et al. Cystathionine-γ-lyase promotes the metastasis of breast cancer via the VEGF signaling pathway[J]. International Journal of Oncology, 2019, 55(2): 473-487. DOI: 10.3892/ijo.2019.4823. doi: 10.3892/ijo.2019.4823
[24]	SIA D, ALSINET C, NEWELL P, et al. VEGF signaling in cancer treatment[J]. Current Pharmaceutical Design, 2014, 20(17): 2834-2842. DOI: 10.2174/13816128113199990590. doi: 10.2174/13816128113199990590 pmid: 23944367
[25]	WALDNER M J, NEURATH M F. Targeting the VEGF signaling pathway in cancer therapy[J]. Expert Opinion on Therapeutic Targets, 2012, 16(1): 5-13. DOI: 10.1517/14728222.2011.641951. doi: 10.1517/14728222.2011.641951 pmid: 22239434
[26]	MARTÍNEZ-REZA I, DÍAZ L, GARCÍA-BECERRA R. Preclinical and clinical aspects of TNF-α and its receptors TNFR1 and TNFR2 in breast cancer[J]. Journal of Biomedical Science, 2017, 24(1): 1-8. DOI: 10.1186/s12929-017-0398-9. doi: 10.1186/s12929-017-0398-9
[27]	LIU W J, LU X Q, SHI P G, et al. TNF-α increases breast cancer stem-like cells through up-regulating TAZ expression via the non-canonical NF-κB pathway[J]. Scientific Reports, 2020, 10(1): 1-11. DOI: 10.1038/s41598-020-58642-y. doi: 10.1038/s41598-020-58642-y
[28]	欧宏宇, 朱海宏, 朱文君, 等. 抗菌肽LL-37通过激活p53信号通路诱导胃癌AGS细胞凋亡[J]. 安徽医科大学学报, 2021, 56(4): 571-576. DOI: 10.19405/j.cnki.issn1000-1492.2021.04.013. doi: 10.19405/j.cnki.issn1000-1492.2021.04.013
[29]	罗浩泉, 林忠顺, 黄小林. 乳腺良恶性肿瘤患者血清催乳素水平变化研究[J]. 中国医学创新, 2018, 15(12): 123-125. DOI: 10.3969/j.issn.1674-4985.2018.12.035. doi: 10.3969/j.issn.1674-4985.2018.12.035
[30]	BORCHERDING D C, HUGO E R, FOX S R, et al. Suppression of breast cancer by small molecules that block the prolactin receptor[J]. Cancers, 2021, 13(11): 2662. DOI: 10.3390/cancers13112662. doi: 10.3390/cancers13112662

序号	生物过程	基因数	P值
1	对雌二醇的反应	8	2.51×10^-9
2	缺乏配体的外源性凋亡信号通路	6	2.02×10^-9
3	对药物的反应	10	4.89×10^-8
4	RNA聚合酶Ⅱ启动子转录的正调控	14	4.45×10^-7
5	RNA聚合酶Ⅱ启动子起始转录	7	1.99×10^-6
6	类固醇激素介导的信号通路	5	1.21×10^-5
7	血管生成	7	1.80×10^-5
8	转录DNA模板正调控	9	3.45×10^-5
9	对脂多糖的反应	6	5.31×10^-5
10	缺氧反应	6	6.65×10^-5

序号	分子功能	基因数	P值
1	酶结合	14	8.27×10^-13
2	类固醇激素受体	7	4.84×10^-9
3	类固醇结合	5	5.57×10^-7
4	RNA聚合酶II转录因子活性,配体激活序列特异性DNA结合	5	1.84×10^-6
5	序列特异性DNA结合	9	3.50×10^-5
6	蛋白质同源二聚活性	10	6.21×10^-5
7	转录因子结合	7	6.78×10^-5
8	核心启动子序列特异性DNA结合	4	1.65×10^-4
9	蛋白质结合	34	3.54×10^-4
10	半胱氨酸型内肽酶活性参与细胞凋亡过程	3	4.63×10^-4

序号	细胞组分	基因数	P值
1	膜筏	6	1.06×10^-4
2	细胞质	19	1.83×10^-4
3	核	25	1.93×10^-4
4	传递神经元	6	2.05×10^-4
序号	细胞组分	基因数	P值
5	核质	17	2.63×10^-4
6	线粒体外膜	5	3.77×10^-4
7	胞膜微囊	4	4.50×10^-4
8	核染色质	5	9.96×10^-4
9	线粒体	10	2.84×10^-3
10	内质网	7	1.12×10^-2

PDB编号	核心靶点	有效活性成分	结合自由能/(kJ·mol^-1)
6OSN	JUN	常春藤皂苷元	-5.3
		反式软骨酸	-5.2
		β-谷甾醇	-6.2
PDB编号	核心靶点	有效活性成分	结合自由能/(kJ·mol^-1)
		芒柄花黄素	-5.4
		豆甾醇	-6.3
2DKO	CASP3	常春藤皂苷元	-8.1
		反式软骨酸	-5.1
		β-谷甾醇	-7.7
		芒柄花黄素	-6.5
		豆甾醇	-8.2
3NT1	PTGS2	常春藤皂苷元	-9.2
		反式软骨酸	-5.9
		β-谷甾醇	-9.1
		芒柄花黄素	-9.3
		豆甾醇	-8.7

Mechanism of the anti-breast cancer effect of Sparganii Rhizoma-Curcumae Rhizoma herbal pair based on network pharmacology and molecular docking

RichHTML

PDF (PC)

Like

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 10

References 30

Related Articles 15

Metrics

Comments

Recommended 0

[1]	LIU Shuang, DONG Hongjing, CHEN Panpan, WANG Xiao. Research progress on the mechanisms by which natural phenolic compounds alleviate hyperuricemia [J]. Shandong Science, 2024, 37(2): 12-19.
[2]	LUO Yaqin, HUANG Wei. Progress in the research on the mechanism of action of Scutellaria baicalensis and its active ingredients in treating ulcerative colitis [J]. Shandong Science, 2024, 37(2): 20-28.
[3]	LIU Kechun, WANG Yongcheng, ZANG Xiaohan, XIA Qing, ZHANG Yun, ZHANG Shanshan, SUN Chen. Advancements in network pharmacology and zebrafish modeling for studying traditional Chinese medicine’s effective substances and mechanisms of action [J]. Shandong Science, 2024, 37(2): 29-35.
[4]	FU Zhaoju, CHENG Guo, LIN Dengmei, LI Jun, ZHANG Nannan. Experimental study and network pharmacological analysis of the anti-inflammatory action mechanism of Mahonia bealei (Fort.) Carr. [J]. Shandong Science, 2024, 37(1): 24-31.
[5]	ZHANG Hanxiao, LIU Yuran, LIU Yuan, NIU Zichen. A multitask learning model for the prediction of short-term subway passenger flow [J]. Shandong Science, 2024, 37(1): 95-106.
[6]	CHEN Chun, QI Daqing, PAN Jingwen. Clinical significance of stromal cell score in gastric cancer and intervention with Weifuchun capsules [J]. Shandong Science, 2023, 36(6): 38-47.
[7]	MU Nana, LIAO Binbin, LI Zhen, LI Jipin, LI Yihua, WANG Ying, CHEN Xubing. Investigating the mechanism of action of Elephantopus scaber L. in the treatment of ulcerative colitis based on network pharmacology and molecular docking [J]. Shandong Science, 2023, 36(6): 48-55.
[8]	HE Zhenbo, ZHANG Li, GAO Mingxin, LUAN Lingyu. Research progress of green scale inhibitors for circulating cooling water [J]. Shandong Science, 2023, 36(5): 102-120.
[9]	WANG Yifan, ZHANG Zhe, TIAN Caijun. Mechanism of Sanhuang Xiexin decoction in treatment of Alzheimer's disease based on network pharmacology and molecular docking method [J]. Shandong Science, 2023, 36(5): 19-26.
[10]	FU Mengya, AO Huihao, BU Chao, PENG Tangyi, WU Deling, HAN Yanquan, HONG Yan. Forecast analysis of the quality markers of Zingiberis Rhizoma based on fingerprints and network pharmacology [J]. Shandong Science, 2023, 36(4): 35-41.
[11]	WEN Yuya, DONG Ting, JIANG Zhangsheng, CHEN Jie, TIAN Liwei, ZHAO Chenling, TANG Lulu. The mechanism of Gandouling tablet in alleviating hepatolenticular degeneration neuroinflammation via the regulation of the TLR4/NF-κB/NLRP3 signaling pathway [J]. Shandong Science, 2023, 36(4): 42-51.
[12]	YIN Zhipeng, GAO Yunyun, LIU Wenwen, GUO Pengbo, ZHAO Yinghui. Exploring the mechanism of Xiangsha Liujunzi Decoction in treating Helicobacter pylori-associated gastritis based on network pharmacology and molecular docking technology [J]. Shandong Science, 2023, 36(4): 52-60.
[13]	SUN Tiefeng, DONG Limin, JIAO Ziqi, WANG Ping. Exploration of the dosing pattern and anti-respiratory syncytial virus mechanism of traditional Chinese medicine based on data mining and network pharmacology [J]. Shandong Science, 2023, 36(3): 1-9.
[14]	ZHU Jie, WANG Zheng, LIANG Yanni. The mechanism of Xiaoqinglong Decoction in treatment of COVID-19 based on network pharmacology [J]. Shandong Science, 2023, 36(3): 10-17.
[15]	DONG Pengjun, CAI Bin. Action mechanism of the herb pair Aurantii Fructus Immaturus-Magnoliae Officinalis Cortex in the treatment of slow transit constipation based on network pharmacology and metabolomics [J]. Shandong Science, 2023, 36(3): 18-26.